Abstract
Nineteen HIV-seropositive antiretroviral therapy-naive and asymptomatic individuals (200-500 CD4/μl) were enrolled in a prospective study aimed at analyzing the immunologic and virologic effects of two different combinations of nucleoside reverse transcriptase inhibitors (AZT+ddI and AZT+3TC), and randomly assigned to one of the treatment group. Immunologic (CD4 and CD8 counts, mitogen-stimulated cytokine production, unstimulated and mitogen-stimulated apoptosis) and virologic (HIV viral load) determinations were performed pre-therapy and 15, 30, 90, 200 and 360 days after initiation of therapy. Results showed that the two combinations had comparable effects on increasing CD4 counts and the CD4/CD8 ratio and in reducing HIV viral load. In contrast, AZT+3TC was more efficient in improving interleukin-2 (IL-2) and interferon gamma (IFNγ) production as well as the type 1/type 2 cytokine ratio and in down modulating the susceptibility of peripheral blood mononuclear cells to in vitro mitogen-stimulated apoptotic cell death. These data suggest that the combination of AZT+3TC has a stronger effect on potentially beneficial immune parameters (IL-2 production; reduction of apoptosis) than the one between AZT+ddI. The combination of AZT+3TC could be more advantageous in the therapy of HIV infection even when used in association with a protease inhibitor. Copyright (C) 2000 Elsevier Science B.V.
| Original language | English |
|---|---|
| Pages (from-to) | 171-179 |
| Number of pages | 9 |
| Journal | Antiviral Research |
| Volume | 46 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 1 2000 |
Fingerprint
Keywords
- Antiviral therapy
- Apoptosis
- Cytokine
- HIV infection
- Immunology
ASJC Scopus subject areas
- Virology
- Pharmacology
Cite this
Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection. / Piconi, Stefania; Trabattoni, Daria; Fusi, Maria Luisa; Milazzo, Francesco; Dix, Lynn P.; Rizzardini, Giuliano; Colombo, Fulvia; Bray, Dorothy; Clerici, Mario.
In: Antiviral Research, Vol. 46, No. 3, 01.06.2000, p. 171-179.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection
AU - Piconi, Stefania
AU - Trabattoni, Daria
AU - Fusi, Maria Luisa
AU - Milazzo, Francesco
AU - Dix, Lynn P.
AU - Rizzardini, Giuliano
AU - Colombo, Fulvia
AU - Bray, Dorothy
AU - Clerici, Mario
PY - 2000/6/1
Y1 - 2000/6/1
N2 - Nineteen HIV-seropositive antiretroviral therapy-naive and asymptomatic individuals (200-500 CD4/μl) were enrolled in a prospective study aimed at analyzing the immunologic and virologic effects of two different combinations of nucleoside reverse transcriptase inhibitors (AZT+ddI and AZT+3TC), and randomly assigned to one of the treatment group. Immunologic (CD4 and CD8 counts, mitogen-stimulated cytokine production, unstimulated and mitogen-stimulated apoptosis) and virologic (HIV viral load) determinations were performed pre-therapy and 15, 30, 90, 200 and 360 days after initiation of therapy. Results showed that the two combinations had comparable effects on increasing CD4 counts and the CD4/CD8 ratio and in reducing HIV viral load. In contrast, AZT+3TC was more efficient in improving interleukin-2 (IL-2) and interferon gamma (IFNγ) production as well as the type 1/type 2 cytokine ratio and in down modulating the susceptibility of peripheral blood mononuclear cells to in vitro mitogen-stimulated apoptotic cell death. These data suggest that the combination of AZT+3TC has a stronger effect on potentially beneficial immune parameters (IL-2 production; reduction of apoptosis) than the one between AZT+ddI. The combination of AZT+3TC could be more advantageous in the therapy of HIV infection even when used in association with a protease inhibitor. Copyright (C) 2000 Elsevier Science B.V.
AB - Nineteen HIV-seropositive antiretroviral therapy-naive and asymptomatic individuals (200-500 CD4/μl) were enrolled in a prospective study aimed at analyzing the immunologic and virologic effects of two different combinations of nucleoside reverse transcriptase inhibitors (AZT+ddI and AZT+3TC), and randomly assigned to one of the treatment group. Immunologic (CD4 and CD8 counts, mitogen-stimulated cytokine production, unstimulated and mitogen-stimulated apoptosis) and virologic (HIV viral load) determinations were performed pre-therapy and 15, 30, 90, 200 and 360 days after initiation of therapy. Results showed that the two combinations had comparable effects on increasing CD4 counts and the CD4/CD8 ratio and in reducing HIV viral load. In contrast, AZT+3TC was more efficient in improving interleukin-2 (IL-2) and interferon gamma (IFNγ) production as well as the type 1/type 2 cytokine ratio and in down modulating the susceptibility of peripheral blood mononuclear cells to in vitro mitogen-stimulated apoptotic cell death. These data suggest that the combination of AZT+3TC has a stronger effect on potentially beneficial immune parameters (IL-2 production; reduction of apoptosis) than the one between AZT+ddI. The combination of AZT+3TC could be more advantageous in the therapy of HIV infection even when used in association with a protease inhibitor. Copyright (C) 2000 Elsevier Science B.V.
KW - Antiviral therapy
KW - Apoptosis
KW - Cytokine
KW - HIV infection
KW - Immunology
UR - http://www.scopus.com/inward/record.url?scp=0034212692&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034212692&partnerID=8YFLogxK
U2 - 10.1016/S0166-3542(00)00076-0
DO - 10.1016/S0166-3542(00)00076-0
M3 - Article
C2 - 10867155
AN - SCOPUS:0034212692
VL - 46
SP - 171
EP - 179
JO - Antiviral Research
JF - Antiviral Research
SN - 0166-3542
IS - 3
ER -